This product is a β-lactamase-stable cephalosporin bactericidal antibiotic that works by blocking the synthesis of the main cell wall polymer, peptidoglycan. Because it can quickly penetrate the bacterial cell wall and bind to the target enzyme (penicillin binding protein) with high affinity, it can kill a wide spectrum of Gram-negative and Gram-positive pathogens at low concentrations.

This product is a β-lactamase-stable cephalosporin bactericidal antibiotic that works by blocking the synthesis of the main cell wall polymer, peptidoglycan. Because it can quickly penetrate the bacterial cell wall and bind to the target enzyme (penicillin binding protein) with high affinity, it can kill a wide spectrum of Gram-negative and Gram-positive pathogens at low concentrations. Many strains that are resistant to other injectable cephalosporins or aminoglycosides are still sensitive to this product.

Ceftriaxone is a long-acting, broad-spectrum cephalosporin that produces antibacterial effects by inhibiting the synthesis of cell walls. It has a strong bactericidal effect on both Gram-positive and Gram-negative bacteria. It is highly stable to beta-lactamase (including penicillinase and cephalosporinase). In vitro and clinical trials have shown that ceftriaxone sodium has high antibacterial activity against the following Gram-negative bacilli: Escherichia coli, Klebsiella, Proteus mirabilis, indole-positive Proteus, Salmonella, Shigella and other r/Enterobacteriaceae and Haemophilus influenzae; it also has good antibacterial effects on Gram-negative cocci such as meningococci and gonococci; Gram-positive cocci such as pneumococci, Streptococcus pyogenes, Streptococcus viridans, and Streptococcus bovis are all sensitive to this product; it also has a certain antibacterial effect on Staphylococcus aureus, but the antibacterial effect is poorer than that of the above-mentioned Gram-positive cocci. Pseudomonas aeruginosa and Acinetobacter are less sensitive to this product. It also has antibacterial activity against some anaerobic bacteria such as Bacteroides fragilis, Clostridium, and Peptococcus.

Ceftriaxone is a long-acting, broad-spectrum cephalosporin that produces antibacterial effects by inhibiting the synthesis of cell walls. It has a strong bactericidal effect on both Gram-positive and Gram-negative bacteria. It is highly stable to beta-lactamase (including penicillinase and cephalosporinase). In vitro and clinical trials have shown that ceftriaxone sodium has high antibacterial activity against the following Gram-negative bacilli: Escherichia coli, Klebsiella, Proteus mirabilis, indole-positive Proteus, Salmonella, Shigella and other r/Enterobacteriaceae and Haemophilus influenzae; it also has good antibacterial effects on Gram-negative cocci such as meningococci and gonococci; Gram-positive cocci such as pneumococci, Streptococcus pyogenes, Streptococcus viridans, and Streptococcus bovis are all sensitive to this product; it also has a certain antibacterial effect on Staphylococcus aureus, but the antibacterial effect is poorer than that of the above-mentioned Gram-positive cocci. Pseudomonas aeruginosa and Acinetobacter are less sensitive to this product. It also has antibacterial activity against some anaerobic bacteria such as Bacteroides fragilis, Clostridium, and Peptococcus.

Cefepime is a broad-spectrum fourth-generation cephalosporin that achieves bactericidal effects by inhibiting the biosynthesis of bacterial cell walls. It is effective against both Gram-positive and Gram-negative bacteria, is highly resistant to hydrolysis by most beta-lactamases, and can quickly penetrate into the cells of Gram-negative bacteria. Its target molecule is penicillin-binding protein (PBP). In vitro and clinical studies have confirmed that this product is active against most of the following microorganisms: Gram-negative aerobic microorganisms such as Enterobacter, Klebsiella pneumoniae, Escherichia coli, Proteus mirabilis, and Pseudomonas aeruginosa; Gram-positive aerobic microorganisms such as Staphylococcus aureus (only for methicillin-sensitive strains), Streptococcus pyogenes (Group A Streptococcus), Streptococcus pneumoniae, etc.